📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Lymphocyte development & homeostasis.

Lead Research Organisation: Babraham Institute
Department Name: UNLISTED

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The intrinsic lifespan of lymphocyte subsets increases as the cells progress through the immature, naïve and memory stages. This represents a paradigm for the reprogramming of cell lifespan in vivo but the molecular basis for this is incompletely understood. For example, while naïve B and T cells may survive for months, memory B and T cells last for years, perhaps reflecting a greater potential for self-renewal [49]. Maintenance within the naïve pool is also dependent upon interclonal competition and memory cells are far less subject to this competition which may also contribute to their increased lifespan. The size of the pool of naive lymphocytes is limited by competition for trophic factors such as the TNF superfamily member BAFF (tnfsf13B) in the case of Marginal Zone (MZ) and Follicular (B2) B cell subsets and IL-7 in the case of T cells [50]. B1 B cells, by contrast, maintain self-renewal independently of BAFF and the factors that regulate the lifespan of certain epithelial T cell subsets remain unknown. These features of lymphocyte lifespan are linked to the extrinsic and intrinsic factors that dictate the upper limits of the number of lymphocytes at each developmental stage. This may be linked to specific signalling pathways that regulate organ size, e.g. the PI3K pathway. For instance, the number of marginal zone B cells is proportional to the activity of the PI3K pathway within B cells. The PI3K pathway in T cells determines the number of T-follicular helper cells and, in a non-cell autonomous manner, the number of germinal centre (GC) B cells. Our identification of genes and pathways that regulate lymphocyte development and survival now permits us to investigate mechanisms through which these pathways function and connect to other components of lymphocyte homeostasis (e.g. the Bcl2 pathway). In addition, we have found that TIS11b is necessary for the development and turnover of the B1 and MZ B cell pools. This finding not only confirms the need to uncover how signalling pathways regulate the transcriptional programmes affecting cell fate but also emphasise the profound effects that the control of mRNA stability and translational efficiency can impart. So far, three out of the 8 mouse GIMAP GTPases have been shown to influence lymphocyte survival, either positively (GIMAPs 1 and 5) or negatively (GIMAP4 – an accelerator of apoptosis) [7, 51-52]. Given their strong expression in resting lymphocytes, roles can be expected for the remaining family members shared across species, namely the cytosolic members GIMAP6, 8 and 7/9. We predict that, in common with most GTPases, the cell biological role of the GIMAPs will lie in the re-fashioning of parts of the lymphocytes’ intracellular membraneous organelles in response to developmental, homeostatic and activation requirements.

Planned Impact

unavailable

Publications

10 25 50
 
Title PI 3-kinase delta enhances axonal PIP3 to support axon regeneration in the adult CNS 
Description Peripheral nervous system (PNS) neurons support axon regeneration into adulthood, whereas central nervous system (CNS) neurons lose regenerative ability after development. To better understand this decline whilst aiming to improve regeneration, we focused on phosphoinositide 3-kinase (PI3K) and its product phosphatidylinositol (3,4,5)-trisphosphate (PIP3). We demonstrate that adult PNS neurons utilise two catalytic subunits of PI3K for axon regeneration: p110a and p110d. However, in the CNS, axonal PIP3 decreases with development at the time when axon transport declines and regenerative competence is lost. Overexpressing p110a in CNS neurons had no effect; however, expression of p110d restored axonal PIP3 and increased regenerative axon transport. p110d expression enhanced CNS regeneration in both rat and human neurons and in transgenic mice, functioning in the same way as the hyperactivating H1047R mutation of p110a. Furthermore, viral delivery of p110d promoted robust regeneration after optic nerve injury. These findings establish a deficit of axonal PIP3 as a key reason for intrinsic regeneration failure and demonstrate that native p110d facilitates axon regeneration by functioning in a hyperactive fashion. 
Type Of Art Film/Video/Animation 
Year Produced 2020 
URL https://axonrepair2020.figshare.com/articles/poster/PI_3-kinase_delta_enhances_axonal_PIP3_to_suppor...
 
Title PI 3-kinase delta enhances axonal PIP3 to support axon regeneration in the adult CNS 
Description Peripheral nervous system (PNS) neurons support axon regeneration into adulthood, whereas central nervous system (CNS) neurons lose regenerative ability after development. To better understand this decline whilst aiming to improve regeneration, we focused on phosphoinositide 3-kinase (PI3K) and its product phosphatidylinositol (3,4,5)-trisphosphate (PIP3). We demonstrate that adult PNS neurons utilise two catalytic subunits of PI3K for axon regeneration: p110a and p110d. However, in the CNS, axonal PIP3 decreases with development at the time when axon transport declines and regenerative competence is lost. Overexpressing p110a in CNS neurons had no effect; however, expression of p110d restored axonal PIP3 and increased regenerative axon transport. p110d expression enhanced CNS regeneration in both rat and human neurons and in transgenic mice, functioning in the same way as the hyperactivating H1047R mutation of p110a. Furthermore, viral delivery of p110d promoted robust regeneration after optic nerve injury. These findings establish a deficit of axonal PIP3 as a key reason for intrinsic regeneration failure and demonstrate that native p110d facilitates axon regeneration by functioning in a hyperactive fashion. 
Type Of Art Film/Video/Animation 
Year Produced 2020 
URL https://axonrepair2020.figshare.com/articles/poster/PI_3-kinase_delta_enhances_axonal_PIP3_to_suppor...
 
Description Our studies on lymphocyte development and homeostasis discovered new roles for a family of poorly characterised gene in T and B cell homeostasis. It now turns out that these genes the GIMAPs are linked to human immunodeficiency and our expertise and research tools are accelerating the discovery of the nature of this immunodeficiency. Work on PI3K extended our understanding of its role in the survival of lymphocytes in normal and pathological situations; this helps understand how and when use of small molecule inhibitors of P110delta in B cell malignancy (this builds on a long-term investment BBSRC made in our science. We also found P110delta was importation regulatory T cells where its absence undermined their function; an observation that may explain its efficacy in some tumours, but also explain its unwanted side effects. Work on RNA binding proteins broke new ground on the mechanisms of lymphocyte development and activation. We discovered that they were fundamental for regulating quiescence a finding that has implications for many cells outside of the immune system. It also has implications for malignancy and it is becoming increasingly evident that we have discovered a new class of tumour suppressors. This was not an expected result at the outset. We also completed and published studies of the role of epithelial lymphocytes which are important for maintain tissue homeostasis at barrier surfaces. We discovered that stress responses were instructive in lymphocyte cell fate decisions.


Overall, we discovered fundamental new knowledge about lymphocyte development and homeostasis. This has implications for biology of ageing-for the formation of the immune system and how it turns against our own bodies as we age. This thinking has underpinned new approaches towards understanding how lymphocytes contribute to the infection-free inflammatory "disease" that occurs as we age. Our discoveries have led to significant new funding and recognition including industrial funding. Of note work is being taken forward in new projects such as that funded by the Global Challenges Research Fund. Other work has attracted Industry attention and we are part of a research alliance with CRT funded by Celgene. Based on our work on B cells we have also become part of a H2020-MCSA Innovative Training Network.
Exploitation Route see the above answer
Sectors Healthcare

 
Description work on Pi3k has underpinned drug discovery and led to treatment of CLL and lymphoma.the work on RNA binding proteins is leading to new insights into development and function of the immune system. This is having impact e.g. see http://commercial.cancerresearchuk.org/cancer-research-uk-announces-drug-discovery-collaboration-celgene-corporation
First Year Of Impact 2015
Sector Healthcare
 
Description Gilead Oncology Faculty
Geographic Reach Multiple continents/international 
Policy Influence Type Influenced training of practitioners or researchers
Impact Following the EMA approval of Zydelig® (idelalisib) in September 2014, and the presentation of new data on idelalisib at ASH 2014, Gilead medical affairs launched a new idelalisib speaker programme, known as "Gilead Oncology Faculty". This medically led, non-promotional activity aims to provide engaged experts the opportunity to be trained on idelalisib data of high quality and scientific content (on label; new indications and new oncology drugs within the Gilead portfolio to be added according to their approval) and subsequently, to give Gilead affiliates across the EMEA region engagement opportunities with registered haematology experts for their local / regional non-promotional speaking events.
URL https://www.gileadfaculty.com
 
Description Wellcome science Interview committee
Geographic Reach National 
Policy Influence Type Participation in a guidance/advisory committee
URL https://wellcome.org/grant-funding/guidance/funding-application-advisory-committees/science-intervie...
 
Description BBSRC GCRF Data & Resources
Amount £171,733 (GBP)
Funding ID BBS/OS/GC/000008A 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 09/2016 
End 07/2017
 
Description Celgen CRT Translation Alliance
Amount £500,000 (GBP)
Organisation Cancer Research Technology (CRT) 
Sector Private
Country United Kingdom
Start 02/2018 
End 01/2021
 
Description EMBO Young Investigator Award
Amount € 25,000 (EUR)
Organisation European Molecular Biology Organisation 
Sector Charity/Non Profit
Country Germany
Start 01/2017 
End 12/2020
 
Description ERC starting grant
Amount € 1,500,000 (EUR)
Funding ID LS6_637801 
Organisation European Research Council (ERC) 
Sector Public
Country Belgium
Start 05/2015 
End 05/2020
 
Description GCRF Networks in Vaccines Research and Development
Amount £1,000,000 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 11/2017 
End 10/2022
 
Description High-throughput automation of sequencing library generation for Wellcome Trust-funded research at the Babraham Institute
Amount £244,089 (GBP)
Funding ID 208380/Z/17/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2018 
End 01/2019
 
Description ITN
Amount € 36,052,456 (EUR)
Funding ID COSMIC 
Organisation European Commission 
Department Horizon 2020
Sector Public
Country European Union (EU)
Start 01/2018 
End 12/2022
 
Description Initial Training Networks (ITN): Horizon 2020
Amount € 6,000,000 (EUR)
Funding ID ENLIGHT-TEN - AMD-675395-1 
Organisation European Commission 
Department Horizon 2020
Sector Public
Country European Union (EU)
Start 09/2015 
End 09/2019
 
Description Investigator Award
Amount £1,300,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2017 
End 03/2022
 
Description Lost-Tfh) Lost in space: How spatial dysregulation of T follicular helper cells impairs vaccine responses in ageing
Amount £1,723,611 (GBP)
Funding ID EP/X022382/1 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 07/2022 
End 08/2027
 
Description Mechanisms of regulatory T Treg cell stability in health and disease
Amount £96,696 (GBP)
Funding ID BB/P504555/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 08/2016 
End 09/2020
 
Description Molecular regulation of NK cell functional maturation by the transcription factor BACH2
Amount £658,607 (GBP)
Funding ID MR/S024468/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 05/2019 
End 05/2022
 
Description Resolving mechanisms of gene regulation within the immune system using forward genetics
Amount £200,000 (GBP)
Organisation Lister Institute of Preventive Medicine 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2017 
End 10/2019
 
Description Small Molecule Drug Discovery Award
Amount £300,000 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2017 
End 01/2020
 
Title Guidelines for the use of flow cytometry and cell sorting in immunological studies 
Description "Guidelines for the use of flow cytometry and cell sorting in immunological studies" represent a community effort to collect the currently accepted best methods for monitoring most of the variation of the major players of immune system (along with their organelles and functionality) and include standards for data interpretation, as well as cautions about technical issues. One aspect of the guidelines concerns data reproducibility, a topic that has recently attracted considerable attention. Therefore, the guidelines are meant to help researchers avoid potential pitfalls that could drastically alter the interpretation of their data. 
Type Of Material Technology assay or reagent 
Year Produced 2017 
Provided To Others? Yes  
Impact paper has been widely dowloaded, read and cited 
URL https://onlinelibrary.wiley.com/doi/full/10.1002/eji.201646632
 
Title mouse model 
Description We have generated novel mouse models. The details of many of these are available in our peer-reviewed papers. A number of models are still under evaluation 
Type Of Material Model of mechanisms or symptoms - mammalian in vivo 
Year Produced 2017 
Provided To Others? Yes  
Impact see pubished papers 
 
Title plasmids and libraries 
Description plasmids and libraries. there are multiple entires on the resource 
Type Of Material Technology assay or reagent 
Year Produced 2022 
Provided To Others? Yes  
Impact publications 
URL https://www.addgene.org/Martin_Turner/
 
Description Celgene CRT Alliance 
Organisation Cancer Research Technology (CRT)
Country United Kingdom 
Sector Private 
PI Contribution The Celgene CRT alliances been described here http://commercial.cancerresearchuk.org/cancer-research-uk-announces-drug-discovery-collaboration-celgene-corporation we are one of the academic partners
Collaborator Contribution This is a complex collaboration involving MRC, BBSRC, Wellcome and CRUK funded groups
Impact many, but specifically I have extended the contract of a talented postdoc in my lab. I would add that this is new money from Celgene which is a US company-so this is a genuine economic impact in the UK
Start Year 2018
 
Description Collaboration with Jernej Use 
Organisation Francis Crick Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution shared expertise
Collaborator Contribution shared expertise
Impact https://www.biorxiv.org/content/10.1101/2021.08.27.457890v1
Start Year 2014
 
Description Depleting regulatory T (Treg) cells in cancer 
Organisation Cancer Research Technology (CRT)
Country United Kingdom 
Sector Private 
PI Contribution We have generated preliminary data that has formed the basis for a drug development programme aimed at generating new immune based therapies for cancer that work by depleting immunosuppressive regulatory T cells accumulating within tumours
Collaborator Contribution A discussion is currently underway to undertake an industrial collaboration with CRUK-TDL
Impact Not yet delivered
Start Year 2018
 
Description Drug discovery programme targeting the immunosuppressive transcription factor activity of BACH2 
Organisation Cancer Research Technology (CRT)
Country United Kingdom 
Sector Private 
PI Contribution We have previously found that BACH2 promotes tumour immunosuppression by promoting Foxp3+ Treg cell-mediated suppression of CD8+ T cells and IFN-? within tumors (Roychoudhuri et al., J Clin Invest. 2016). This has formed the basis for an on-campus industrial collaboration with Cancer Research Technology (CRT). We aim to develop a cell-based reporter assay for the transcription factor activity of BACH2 in order to perform a high-throughput screen of small molecule inhibitors. The collaboration resulted from a meeting arranged by Martin Turner between LLSD and CRT and was supported by a Babraham Institute Knowledge Exchange and Commercialisation Committee Campus Collaboration Award (£15K). Preliminary data generated formed the basis for a successful application for a CRUK Drug Discovery Award (£300K). We are developing stable reporter cell lines using bioinformatically derived enhancer sequences that are responsive to transcriptional repression by BACH2 and amenable to high-throughput drug screening by our collaborators at CRT.
Collaborator Contribution Performance of a high-throughput drug screen (>200k compounds) using cell-based reporter assays for the transcription factor activity of BACH2 generated in the laboratory.
Impact This collaboration resulted in receipt of further funding - a BI Knowledge Exchange and Commercialisation Committee Campus Collaboration Award (£15K) and a CRUK Drug Discovery Award (£300K)
Start Year 2017
 
Description EM Studies of GIMAP GTPases 
Organisation University of Cambridge
Department Cambridge Institute for Medical Research (CIMR)
Country United Kingdom 
Sector Academic/University 
PI Contribution Provision of cellular materials and specific antibodies
Collaborator Contribution Performance of electron microscopic analysis
Impact Publication: PMID: 21487483
Start Year 2009
 
Description Human Gimap studies 
Organisation University of Oxford
Department Weatherall Institute of Molecular Medicine (WIMM)
Country United Kingdom 
Sector Academic/University 
PI Contribution Advice, reagents.
Collaborator Contribution We have advised on ongoing studies of Gimap proteins in human immunology and mouse model systems. We have provided specific antibody reagents from our collection.
Impact Progress but no outputs as yet.
Start Year 2016
 
Description Katsikis new 
Organisation Erasmus MC
Country Netherlands 
Sector Hospitals 
PI Contribution exchange of reagents and knowhow
Collaborator Contribution exchange of reagents and knowhow
Impact non so far
Start Year 2014
 
Description Transcriptional and epigenetic programmes of lung inflammation 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution A key commercial collaboration between Rahul Roychoudhuri (RR) and GlaxoSmithKline (GSK)/Epinova, which is now supported by two BBSRC CASE awards, aims to understand the transcriptional and epigenetic programmes that promote lung inflammation. We aim to define transcriptional and epigenetic mechanisms by which airway immune homeostasis is maintained by transcriptional and epigenetic regulators.
Collaborator Contribution Support of CASE awards, co-supervision of PhD students, supply of pharmacological agents for use as tool compounds in assessment of epigenetic regulators
Impact We have gained an understanding of how lung inflammation is restrained by suppression of ILC2 activation and promotion of Treg differentiation by the transcription factor BACH2 and are exploring mechanisms by which BACH2 may regulate epigenetic programmes in T cells
Start Year 2016
 
Description Understanding the molecular and cellular basis for the function of agonist antibody-based immunotherapies 
Organisation F-star Therapeutics
Country United Kingdom 
Sector Private 
PI Contribution This collaboration with F-Star Biotechnology Limited aims to understand the molecular and cellular basis for the function of agonist antibody-based immunotherapies in cancer. The work, funded by F-Star, will take place in our laboratory and will be undertaken by a funded postdoctoral scientist. The collaboration is facilitated by the proximity of the Institute to F-Star on the Babraham Research Campus
Collaborator Contribution F-Star have fully funded the research collaboration and are providing reagents for the investigations which will be conducted using pre-clinical mouse models.
Impact Immunology Molecular biology Drug development Bioinformatics
Start Year 2019
 
Description BBC World service interview for Carr et al (2016) 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Discussed the findings reported in our 2016 paper on ageing and the immune system
Year(s) Of Engagement Activity 2016
 
Description BBC radio 4 today programme interview for Carr et al (2016) 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact An interview on BBC radio 4 to discuss the findings reported in our 2016 paper on ageing and the immune system
Year(s) Of Engagement Activity 2016
 
Description BBC radio Cambridge interview for Carr et al (2016) 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Interview to discuss our 2016 publication on Ageing and the Immune system
Year(s) Of Engagement Activity 2016
 
Description BBC radio Scotland interview for Carr et al (2016 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact An interview with BBC radio scotland on our 2016 paper on ageing and the immune system
Year(s) Of Engagement Activity 2016
 
Description Cambridge Bioresource volunteer event, CRUK, Cambridge 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Presented our work on ageing and the response to vaccination to an adult lay audience. This included people who are interested in taking part in research studies.
Year(s) Of Engagement Activity 2016
 
Description Discussed animal research on Cambridge TV 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact I was interviewed for a programme aired on Cambridge TV about the use of animals in research.
Year(s) Of Engagement Activity 2016
URL http://www.cambridge-tv.co.uk/impact-animal-research/
 
Description Interview for French radio for Carr et al (2016) 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact An interview to discuss the findings of our research on ageing and the immune system
Year(s) Of Engagement Activity 2016
 
Description Interview for Swiss Radio (French) Carr et al (2016) 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact An interview to discuss the results reported in our 2016 paper on ageing and the immune system
Year(s) Of Engagement Activity 2016
 
Description Interview with Cambridge TV for Carr et al (2016) 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact An interview about our 2016 publication on ageing and the human immune system
Year(s) Of Engagement Activity 2016
 
Description Interview with Naked Scientists for podcast (2015) 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Interview with the Naked Scientists on our research into Ageing
Year(s) Of Engagement Activity 2015
 
Description Invited speaker at NIH Workshop: Advances in Aging, Immunity, and Chronic Inflammatory Disease 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Presented our work on ageing and vaccination to the NIH, NIA, NIAID and NIDCR Workshop: Advances in Aging, Immunity, and Chronic Inflammatory Disease
Year(s) Of Engagement Activity 2023
URL https://www.nia.nih.gov/research/dab/workshop-advances-aging-immunity-and-chronic-inflammatory-disea...
 
Description Invited speaker: Sanofi Immune Memory Symposium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Michelle Linterman was invited to present at a conference organised by Sanofi Pasteur at their headquarters in France. The presentation was followed by questions and discussion.
Year(s) Of Engagement Activity 2016
 
Description Participation in an activity, workshop or similar - School visit to the Roychoudhuri laboratory for hands-on experience in flow cytometry and cellular immunology 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Schools
Results and Impact The laboratory hosted a group of 6 sixth form school students to undertake a flow cytometry experiment in cellular immunology with bench research, teaching from PhD and Postdocs in the group
Year(s) Of Engagement Activity 2020
 
Description Policy Discussion with Rebecca Jones, Head of Cancer, Ageing and Digipath at Office for Life Sciences DHSC/BEIS, about ageing research in the UK 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact Rebecca leads the Cancer, Ageing and Digipath team in the Office for Life Sciences taking a missions approach to tackling two of the greatest healthcare challenges facing society - Cancer and Ageing - working in partnership with stakeholders across HMG, NHS, academia, patient groups, industry and the third sector. Using developments in research and innovation, the missions will work to improve cancer diagnosis, treatment and care, and towards preventing people developing multiple long-term conditions as they age. Her team also leads an ongoing programme to digitise and use AI in pathology and imaging in the NHS.

She is currently a policy fellow at CSaP (https://www.csap.cam.ac.uk/network/rebecca-jones/) we met to discuss ageing in the UK
Year(s) Of Engagement Activity 2023
 
Description Policy discussion with Dr Adrian Baker, Research Lead in the Innovation, Research, and Life Sciences Group and the Accelerated Access Collaborative at NHS England 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact Dr Baker and I discussed frameworks to facilitate participation in research by the public, and ways that this could be enhanced. We also discussed ways to facilitate the translation of basic research into interventions that have social and economic impact.
Year(s) Of Engagement Activity 2023
URL https://www.csap.cam.ac.uk/network/adrian-baker-nhs/
 
Description Presentation at Glaxo Smith Kline, Stevenage, United Kingdom 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Industry/Business
Results and Impact Presentations from Michelle Linterman and Alice Denton on the basic biology of the response to vaccination, with a specific focus on the biology of stromal cells. The presentations were followed by a discussion.
Year(s) Of Engagement Activity 2016
 
Description Presentation on the use of mouse models in immunology research 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Presentation of the reasons and uses of research using mouse models in immunology research to a large group of local parishioners visiting the Institute for the talk.
Year(s) Of Engagement Activity 2018
 
Description Public talk on Ageing and the immune system at the Cambridge Corn Exchange (2016) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact A public presentation of our work on Ageing and the response to vaccination
Year(s) Of Engagement Activity 2016
 
Description Royal Society Summer Exhibition, 2015: Immune Army 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact We presented our exhibition: "Immune Army: weapons of microscopic destruction"; at the Royal Society Summer exhibition 2015. Many members of my lab participated in the design of the exhibition materials, the accompanying video (https://youtu.be/oMj8UxMPYJU) and at the exhibition itself. I spent two full days at the exhibition. Work on Activated PI3K Delta Syndrome (APDS) and Cancer immunotherapy from my lab featured prominently in this exhibition.
Year(s) Of Engagement Activity 2015
URL http://sse.royalsociety.org/2015/immune-army/
 
Description T.V. interview BBC look east 2017 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Interview on our research on how the response to vaccination changes with age
Year(s) Of Engagement Activity 2016
 
Description Talk at GSK 2014 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Industry/Business
Results and Impact A presentation was given at the Glaxo Smith Klein site in Stevenage, UK on our work on the germinal centre response. Following this visit a joint BBSRC iCASE award was made for a PhD student to be shared between the Babraham Institute and GSK.
Year(s) Of Engagement Activity 2014
 
Description Talk on ageing to local discussion group 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact This was an evening talk to a local discussion group in Great Abington, Cambridgeshire delivered by G.B and Prof Joanna Latimer (University of York) who is a Public Engagement collaborator of the Institute. Our presentation covered both the biology of ageing (illustrated by examples of relevant Babraham science) and sociological aspects of our private and public attitudes to ageing. A wide-ranging and rich discussion took place with the audience of 15-20.
Year(s) Of Engagement Activity 2017
 
Description Visit of School Teachers in the lab 2016 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact Discuss and demonstrate our research to visiting teachers in our laboratory.
Year(s) Of Engagement Activity 2016
 
Description WMD 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact WMD: Weapons on microscopic destruction was a multimedia presentation by students postdocs and project leaders. it involved the use of iPADs, games and fridge magnets to engage discussion of how the immune system works and how it is affected by ageing.

it has been presented multiple times and has engaged many young and older individuals
Year(s) Of Engagement Activity 2014
 
Description open day 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? Yes
Geographic Reach Local
Primary Audience Schools
Results and Impact practical demonstrations and participation in a simple experiment

inspired young people
Year(s) Of Engagement Activity 2006,2007,2008,2009,2010,2011,2012,2013,2014